Novo Nordisk A/S (NYSE:NVO) Cut to Buy at StockNews.com

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.

Several other equities analysts also recently commented on the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $62.88 on Tuesday. Novo Nordisk A/S has a twelve month low of $59.32 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a fifty day simple moving average of $76.55 and a 200 day simple moving average of $92.55. The company has a market capitalization of $282.18 billion, a PE ratio of 19.11, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Victory Capital Management Inc. boosted its position in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after acquiring an additional 30,420 shares during the period. Versant Capital Management Inc bought a new position in Novo Nordisk A/S in the 4th quarter worth approximately $86,000. Finally, Talbot Financial LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at $4,066,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.